Manufacturer Commercial Supply with High Purity and Stable Quality
Chemical Name: Octreotide Acetate
Sequences: D-Phe-c[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr-ol
CAS: 83150-76-9
| Chemical Name | Octreotide Acetate |
| Sequences | D-Phe-c[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr-ol |
| CAS Number | 83150-76-9 |
| CAT Number | RF-API15 |
| Stock Status | In Stock, Production Scale Up to Kilograms |
| Molecular Formula | C49H66N10O10S2 |
| Molecular Weight | 1019.24 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White Powder |
| Solubility | Soluble in water or 1% acetic acid at a concentration of ≥1mg/ml to give a clear, colorless solution |
| Amino Acid Composition | ±10% of theoretical |
| Peptide Purity (By HPLC) | ≥98.0% by area integration |
| Total Impurities | ≤2.0% (By HPLC) |
| Largest Single Impurity | ≤1.0% (By HPLC) |
| Acetate Content | ≤15.0% (By HPLC) |
| Water Content (Karl Fischer) | ≤7.0% |
| Specific Optical Rotation | -45.0°～-55.0°（C=0.5, 95%HAc） |
| Peptide Content (N%) | ≥80.0% |
| Assay | 95%~105% |
| Test Standard | Enterprise Standard |
| Storage | 2.0～8.0℃ |
| Shipping Requirements | Ice Bags, Desiccant Bags |
| Origin of Product | Synthetic |
| Attention | Only for Research, Not for Human Use |
| Usage | Active Pharmaceutical Ingredient (API) |
Package: Vials, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Octreotide Acetate (Sandostatin) is a synthetic peptide analogue of the hormone somatostatin, it is a long-acting somatostatin analog indicated for symptomatic control in acromegaly and gastroenteropancreatic tumors. Other potential uses under investigation include diabetes, psoriasis and Alzheimer's disease. Octreotide acetate (Sandostatin) is a synthetic peptide analogue of the hormone somatostatin. Its actions include inhibition of the pituitary secretion of growth hormone and an inhibition of pancreatic islet cell secretion of insulin and glucagon. Unlike somatostatin, which has a plasma half-life of a few minutes, octreotide has a plasma elimination half-life of 1 to 2 hours. Excretion of the drug is primarily renal. Octreotide reduces gastrointestinal motility and inhibits contraction of the gall bladder.
Octreotide is three times more potent than the native hormone in inhibiting the secretion of growth hormone glucagon and insulin in vivo. Octreotide regulates serum prolactin levels and resolves galactorrhea or (secondary) amenorrhea in acromegaly patients. Hence, this peptide can be considered as a potent therapeutic for acromegaly treatment. Somatostatin analog that is 3-times more potent than the native hormone in inhibiting the secretion of growth hormone.